EUVIMEDEUVIMED entdecken
Open Access

Deletion of PTP4A3 phosphatase in high-grade serous ovarian cancer cells decreases tumorigenicity and produces marked changes in intracellular signaling pathways and cytokine release

John S Lazo, Kelly N Isbell, Sai Ashish Vasa, Danielle C Llaneza, Garnett A Mingledorff, Elizabeth R Sharlow

The Journal of Pharmacology and Experimental Therapeutics · 2025

DOI: 10.1124/jpet.124.002110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025. Verfasst von John S Lazo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Virginia, Charlottesville, Virginia; KeViRx, Inc., Charlottesville, Virginia. Electronic address: lazo@virg…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cytokines, Signal Transduction, Protein Tyrosine Phosphatases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The oncogenic protein tyrosine phosphatase PTP4A3 is frequently overexpressed in human ovarian cancers and is associated with poor patient prognosis. PTP4A3 is thought to regulate multiple oncogenic signaling pathways, including STAT3, SRC, and extracellular signal-regulated kinase. The objective of this study was to generate ovarian cancer cells with genetically depleted PTP4A3, to assess their tumorigenicity, to examine their cellular phenotype, and to uncover changes in their intracellular signaling pathways and cytokine release profiles. Genetic deletion of PTP4A3 using CRISPR/CRISPR-associated protein 9 enabled the generation of individual clones derived from single cells isolated from the polyclonal knockout population. We observed a >90% depletion of PTP4A3 protein levels by western blotting in the clonal cell lines compared with the sham-transfected wild-type population. The wild-type and polyclonal knockout cell lines shared similar monolayer growth rates, whereas the isolated clonal populations 2B4, 3C9, and 3C12 exhibited significantly lower monolayer growth characteristics consistent with their lower PTP4A3 levels. The clonal Ptp4a3 knockout cell lines also had substantially lower in vitro colony formation efficiencies compared with the wild-type cells and were less tumorigenic in vivo. The clonal knockout cells were markedly less responsive to interleukin-6-stimulated migration in a scratch wound assay compared with the wild-type cells. Antibody microarray assays documented differences in cytokine release and intracellular phosphorylation patterns in the Ptp4a3-deleted clones. Bioinformatic network analyses indicated alterations in cellular signaling nodes. These biochemical changes could ultimately form the foundation for pharmacodynamic endpoints useful for emerging anti-PTP4A3 therapeutics. SIGNIFICANCE STATEMENT: Clones of high-grade serous ovarian cancer cells were isolated, in which the oncogenic phosphatase Ptp4a3 gene was deleted using CRISPR/CRISPR-associated protein 9 methodologies. The Ptp4a3-null cells exhibited loss of in vitro proliferation, colony formation, and migration and reduced in vivo tumorigenesis. Marked differences in intracellular protein phosphorylation and cytokine release were seen. The newly developed Ptp4a3 knockout cells should provide useful tools to probe the role of PTP4A3 phosphatase in ovarian cancer cell survival, tumorigenicity, and cell signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCytokinesSignal TransductionProtein Tyrosine PhosphatasesGene DeletionCarcinogenesisFemaleHumansAnimalsMiceCell Line, TumorCell ProliferationNeoplasm Proteins

Stichwörter der Autor:innen

Cytokine and chemokine releaseGene deletionIntracellular network analysisOvarian cancerProtein phosphorylationProtein tyrosine phosphatase

Substanzen

CytokinesProtein Tyrosine PhosphatasesPTP4A3 protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Pharmacology, University of Virginia, Charlottesville, Virginia; KeViRx, Inc., Charlottesville, Virginia. Electronic address: lazo@virginia.edu.
  • KeViRx, Inc., Charlottesville, Virginia.
  • Department of Pharmacology, University of Virginia, Charlottesville, Virginia.
  • Department of Pharmacology, University of Virginia, Charlottesville, Virginia; KeViRx, Inc., Charlottesville, Virginia.

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NIH HHS

Zitieren

APA

Lazo, J. S., Isbell, K. N., Vasa, S. A., Llaneza, D. C., Mingledorff, G. A., & Sharlow, E. R. (2025). Deletion of PTP4A3 phosphatase in high-grade serous ovarian cancer cells decreases tumorigenicity and produces marked changes in intracellular signaling pathways and cytokine release. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.124.002110

Vancouver

Lazo JS, Isbell KN, Vasa SA, Llaneza DC, Mingledorff GA, Sharlow ER. Deletion of PTP4A3 phosphatase in high-grade serous ovarian cancer cells decreases tumorigenicity and produces marked changes in intracellular signaling pathways and cytokine release. The Journal of Pharmacology and Experimental Therapeutics. 2025. doi:10.1124/jpet.124.002110

BibTeX
@article{Lazo2025,
  author = {Lazo, John S and Isbell, Kelly N and Vasa, Sai Ashish and Llaneza, Danielle C and Mingledorff, Garnett A and Sharlow, Elizabeth R},
  title = {Deletion of PTP4A3 phosphatase in high-grade serous ovarian cancer cells decreases tumorigenicity and produces marked changes in intracellular signaling pathways and cytokine release},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2025},
  doi = {10.1124/jpet.124.002110}
}
Kostenlos starten →